• 1. Department of Pediatric Surgery, The Children’s Hospital, Zhejiang University School of Medicine, Hangzhou 310052, China;
  • 2. National Clinical Research Center For Child Health, Hangzhou 310052, China;
  • 3. National Regional Medical Center for Children, Hangzhou 310052, China;
  • 4. Department of Reproductive Genetics, Women's Hospital, Zhejiang University School of Medicine, Hangzhou 310000, China;
Yu Jialing, Email: jialingyu@zju.edu.cn
Export PDF Favorites Scan Get Citation

Leber’s hereditary optic neuropathy (LHON) is a paradigm maternal hereditary eye disease, mainly involving the retinal and macular fibers of the optic disc in the anterior ethmoid plate of the sclera. LHON has the characteristics of sex bias among males and incomplete penetrance. Primary mitochondrial DNA mutations m.11778G>A, m. 14484T>C, m.3460G>A are the molecular basis of LHON. However, other risk factors, such as secondary mitochondrial DNA mutations, mitochondrial haplotypes, nuclear modification genes, estrogen, vitamin B12 and environmental factors, work together to affect its phenotypic expression. The clinical diagnosis of LHON mainly limited to the detection of the primary mutation site of mitochondrial DNA. Therefore, comprehensive analysis of multiple risk factors of LHON will facilitate to construct multi-dimensional model of prevention, diagnosis and treatment system, which provide accurate and individualized medical services for patients. These may alleviate the incidence in LHON families. It also provides new ideas and different angles for the in-depth study of the pathogenesis of LHON.

Citation: Gao Yinglong, Yu Jialing. Research progress of risk factors of Leber’s hereditary optic neuropathy. Chinese Journal of Ocular Fundus Diseases, 2023, 39(7): 600-604. doi: 10.3760/cma.j.cn511434-20220829-00480 Copy

  • Previous Article

    Research progresses on pathogenic genes and related signal pathways of familial exudative vitreoretinopathy
  • Next Article

    The progress of the gene editing therapy of inherited retinal diseases based on CRISPR/Cas9